APGE Apogee Therapeutics, Inc.

CIK 0001974640 40 ready 8-Ks latest September 3, 2026, 8:53 AM ET RSS · JSON

Activity: QUIET 0 filings / 30d vs 1 baseline Risk accumulating: repeated leadership change (7)

Ready 8-Ks 40

Latest filing September 3, 2026, 8:53 AM ET

Top materiality 1.00

Event mix other_material ×21 · earnings ×9 · m_and_a ×4

Sentiment 26 pos · 0 neg · 14 neu

Latest earnings reported 2026-Q1

Executive change recent →

SHENANIGAN SCORE 1 / 7 see the board

Recent 8-K filings for APGE

Highest-materiality recent filing

Apogee completes $10.9B acquisition by AbbVie; shareholders get $135.11/share

September 3, 2026, 8:53 AM ET M&A materiality 1.00 neutral item 1.02 item 2.01 item 3.01 item 3.03 item 5.01 item 5.02 item 5.03 item 9.01 ◈ executive_change ×7

Merger completed Sept 3, 2026; each share converted to $135.11 cash, total equity value ~$10.9B.
Company to delist from Nasdaq; trading suspended Sept 4, 2026, Form 25 to be filed.

Read filing →

September 3, 2026, 8:53 AM ET M&A materiality 1.00 neutral item 1.02 item 2.01 item 3.01 item 3.03 item 5.01 item 5.02 item 5.03 item 9.01 ◈ executive_change ×7

Apogee completes $10.9B acquisition by AbbVie; shareholders get $135.11/share

Merger completed Sept 3, 2026; each share converted to $135.11 cash, total equity value ~$10.9B.
August 11, 2026, 4:00 PM ET M&A materiality 0.80 positive item 5.02 item 5.07

Apogee stockholders approve AbbVie merger; advisory comp proposal fails

Merger proposal approved: 46,508,107 for, 3,885 against, 14,261 abstentions, satisfying a closing condition.
August 10, 2026, 7:19 AM ET M&A materiality 1.00 positive item 2.02 item 9.01

AbbVie to acquire Apogee for $135.11/share (~$10.9B); Q2 results reported

AbbVie to acquire Apogee for $135.11/share cash, ~$10.9B equity value; expected close Q3 2026.
June 22, 2026, 7:45 AM ET M&A materiality 0.85 positive item 1.01 item 5.07 item 7.01 item 8.01 item 9.01 ◈ Material Agreements

AbbVie to acquire Apogee Therapeutics for $135.11/share, ~$10.9B equity value

AbbVie to acquire all outstanding shares of Apogee for $135.11 per share in cash, total equity value ~$10.9 billion.
June 22, 2026, 7:22 AM ET other material materiality 0.60 neutral item 1.01 item 9.01 ◈ Material Agreements ×2

Apogee licenses exclusive worldwide rights to IL-31R antibodies from Paragon with up to $23.25M in milestones

Exclusive worldwide license from Paragon for monospecific antibodies directed to interleukin-31 receptor (IL-31R).
June 12, 2026, 5:01 PM ET other materiality 0.15 neutral item 5.07 ◈ Shareholder Votes ×3

Apogee shareholders elect directors, ratify auditor, approve say-on-pay at 2026 annual meeting

Director nominees Mark C. McKenna, Jennifer Fox, William Jones elected with >44.9M votes each, broker non-votes 1.8M.
May 27, 2026, 6:40 AM ET other material materiality 0.85 positive item 1.01 item 7.01 item 9.01 ◈ Material Agreements

Apogee secures up to $1.3B non-dilutive financing from Blackstone for zumilokibart

$100M upfront received; additional $100M upon Phase 3 enrollment, $200M on positive Phase 3 data.
May 27, 2026, 6:37 AM ET other material materiality 0.85 positive item 7.01 item 8.01 item 9.01

Apogee reports positive Phase 2 Part B data for zumilokibart; mid-dose 65.9% EASI-75 vs 23.4% placebo

Primary endpoint met: 65.9% mid-dose EASI-75 (p<0.001 vs placebo 23.4%) at 16 weeks.
May 11, 2026, 7:59 PM ET earnings materiality 0.85 positive item 2.02 item 9.01 ◈ Earnings Releases

Apogee reports Q1 loss of $74.1M; $1.3B cash; zumilokibart Phase 3 AD on track

Net loss of $74.1M in Q1 2026 vs. $55.3M a year ago; R&D spend $60.8M, G&A $22.0M.
April 24, 2026, 7:59 PM ET leadership materiality 0.45 neutral item 5.02

Two directors resign from Apogee board; board shrinks from 9 to 7

Andrew Gottesdiener, M.D. and Peter Harwin notified Board of resignations effective May 11, 2026.
March 25, 2026, 7:59 PM ET other material materiality 0.75 neutral item 1.01 item 9.01 ◈ Material Agreements

Apogee Therapeutics prices public offering of 5M shares at $70, net ~$377.4M

5,000,000 shares offered at $70 per share; underwriters' option for 750,000 shares exercised in full.
March 23, 2026, 7:59 PM ET other material materiality 0.80 positive item 7.01 item 8.01 item 9.01

Apogee reports positive Phase 2 52-week zumilokibart data; durable maintenance with 3- and 6-month dosing

EASI-75 maintained in 75% (3-month) and 85% (6-month) of Week 16 responders; vIGA 0/1 maintained in 86% and 78%.
March 2, 2026, 6:59 PM ET earnings materiality 0.55 neutral item 2.02 item 9.01

Apogee Therapeutics FY2025 net loss $255.8M; cash $902.9M; zumilokibart milestones

Net loss $255.8M (FY2024: $182.1M); R&D expense $214.7M (FY2024: $167.9M).
January 6, 2026, 6:59 PM ET other material materiality 0.65 positive item 7.01 item 8.01 item 9.01

Positive Phase 1b asthma data for zumilokibart; FeNO reduction 60%, durable to 32 weeks; 2026 milestones

Zumilokibart showed maximum mean FeNO reduction of 45 ppb (60% decrease) after single 720 mg dose; suppression durable through 16 weeks in all patients and up to 32 weeks in some.
November 10, 2025, 6:59 PM ET other material materiality 0.85 positive item 2.02 item 7.01 item 9.01

Apogee Q3 net loss $65M; APG333 half-life ~55 days supports quarterly dosing; cash $913M, runway into 2H 2028

Q3 2025 net loss $65.0M vs $49.0M YoY; cash and securities $588.9M pre-offering, $913M pro forma post-$345M equity offering.
October 10, 2025, 7:59 PM ET other material materiality 0.85 neutral item 1.01 item 8.01 item 9.01

Apogee (APGE) raises $323M, updates APG777 atopic dermatitis and asthma trials

Offering of 6.95M shares at $41 plus pre-funded warrants and full underwriter option exercise, net proceeds ~$323.3M.
August 11, 2025, 7:59 PM ET earnings materiality 0.70 positive item 2.02 item 9.01

Apogee reports positive APG777 Phase 2 data and Q2 net loss of $66.1M

APG777 APEX Part A met primary endpoint: 71.0% EASI reduction vs 33.8% placebo (p<0.001).
July 7, 2025, 7:59 PM ET other material materiality 0.90 positive item 7.01 item 8.01 item 9.01

Apogee: Phase 2 APG777 hits all endpoints; EASI-75 66.9% (42.5% placebo-adjusted), safety favorable

APEX Part A met primary endpoint: 71% mean EASI reduction vs 33.8% placebo (p<0.001).
June 23, 2025, 7:59 PM ET other materiality 0.15 neutral item 5.07

Apogee Therapeutics shareholders elect directors and ratify auditor at 2025 annual meeting

Elected Class II directors: Bollinger (35.1M for, 4.3M withheld), Kiselak (39.2M for), Shah (25.8M for, 13.6M withheld).
May 12, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 7.01 item 8.01 item 9.01

Apogee reports Q1 net loss $55.3M; positive APG808 Phase 1b data with 53% FeNO suppression

Q1 net loss $55.3M vs $32.1M YoY; cash $681.4M supports runway into Q1 2028.
March 11, 2025, 7:59 PM ET other material materiality 0.60 neutral item 1.01

Apogee Therapeutics enters manufacturing agreement with Samsung Biologics for APG777 drug substance

Master Services Agreement with Samsung Biologics for manufacture and supply of APG777 drug substance for clinical development and commercial sale if approved.
March 3, 2025, 6:59 PM ET other material materiality 0.80 positive item 2.02 item 7.01 item 9.01

Apogee reports positive interim Phase 1 APG990 data with ~60-day half-life; 2024 net loss $182.1M

APG990 demonstrated ~60-day half-life, supporting every 3- and 6-month maintenance dosing; well tolerated up to 1,200 mg.
February 3, 2025, 6:59 PM ET other material materiality 0.70 positive item 7.01 item 8.01 item 9.01

Apogee doses first patient in Part B of Phase 2 APEX trial for APG777 in atopic dermatitis

Part A enrolled 123 patients (exceeded ~110 target) randomized 2:1 APG777 vs placebo; >90% power for primary endpoint.
December 10, 2024, 6:59 PM ET other material materiality 0.60 neutral item 7.01 item 8.01 item 9.01

Apogee doses first healthy volunteers in Phase 1 trial of TSLP antibody APG333

APG333 is a novel half-life extended monoclonal antibody targeting TSLP for asthma, COPD, and I&I conditions.
December 2, 2024, 6:59 PM ET other material materiality 0.75 positive item 7.01 item 8.01 item 9.01

Apogee: APG808 Phase 1 shows 55-day half-life; APG777 data support annual dosing; Phase 2 topline now mid-2025

APG808 interim Phase 1: half-life ~55 days, supports every 2-3 month dosing; well-tolerated; Phase 1b in asthma expected 1H 2025.
November 12, 2024, 6:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01

Apogee Therapeutics Reports Q3 2024 Financial Results and Pipeline Progress

Cash, cash equivalents and marketable securities of $753.8M as of Sept 30, 2024, with runway into 2028.
October 24, 2024, 7:59 PM ET other material materiality 0.70 positive item 7.01 item 9.01

Apogee reports positive Phase 1 APG777 data: half-life ~75 days, sustained PD effect up to 9 months

APG777 half-life of ~75 days is about 3–5× longer than currently approved moderate-to-severe AD treatments.
August 19, 2024, 7:59 PM ET other material materiality 0.60 positive item 7.01 item 8.01 item 9.01

Apogee doses first healthy volunteers in Phase 1 trial of OX40L antibody APG990 for atopic dermatitis

Initiated dosing in Phase 1 trial of APG990, a half-life extended OX40L antibody, enrolling ~40 healthy volunteers in 5 cohorts.
August 12, 2024, 7:59 PM ET earnings materiality 0.60 neutral item 2.02 item 8.01 item 9.01

Apogee reports Q2 net loss $33.8M; cash $789.6M; APG777 Phase 2 dosing started

Q2 2024 net loss $33.8M ($18.9M in Q2 2023); R&D expenses $33.2M, up from $13.9M.
June 7, 2024, 7:59 PM ET other materiality 0.10 neutral item 5.07

Apogee Therapeutics shareholders elect three Class I directors, ratify auditor, approve option grant

Elected Andrew Gottesdiener, Peter Harwin, and Michael Henderson as Class I directors with >33.8M votes for each.
May 28, 2024, 7:59 PM ET leadership materiality 0.30 neutral item 5.02 item 7.01 item 9.01 ◈ executive_change

Apogee Therapeutics appoints Lisa Bollinger, MD to board of directors

Lisa Bollinger, MD elected as Class II director, effective May 28, 2024.
May 15, 2024, 7:59 PM ET other material materiality 0.70 positive item 7.01 item 9.01

Apogee starts Phase 2 AD trial for APG777; Phase 1 shows ~75-day half-life

Initiated dosing in Phase 2 trial of APG777 for moderate-to-severe atopic dermatitis (AD).
May 13, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01 ◈ Earnings Releases

Apogee reports Q1 net loss $32.1M, cash $816M, advances pipeline with Phase 2 start for APG777 and $483M raise

Net loss $32.1M vs $12.5M YoY; R&D expenses $28.7M (up from $8.5M) as pipeline progresses.
March 25, 2024, 7:59 PM ET other material materiality 0.55 positive item 7.01 item 9.01

Apogee Therapeutics doses first volunteers in Phase 1 trial of APG808 for COPD and asthma

First participants dosed in Phase 1 healthy volunteer trial of APG808, a half-life extended IL-4Rα mAb.
March 5, 2024, 6:59 PM ET other material materiality 0.85 positive item 2.02 item 7.01 item 9.01

Apogee reports positive Phase 1 data for APG777 with ~75-day half-life; FY2023 net loss $84M

APG777 Phase 1 interim data: half-life ~75 days, deep pSTAT6 and TARC suppression for ~3 months, well tolerated.
March 5, 2024, 6:59 PM ET other material materiality 0.30 neutral item 7.01 item 9.01

Apogee releases APG777 Phase 1 data in web presentation; no specific results in 8-K

Phase 1 first-in-human data for APG777 posted to company website on March 5, 2024.
November 13, 2023, 6:59 PM ET earnings materiality 0.65 positive item 2.02 item 9.01 ◈ Earnings Releases

Apogee Q3 net loss $20.8M; cash $422.9M; APG777 Phase 1 dosed ahead of schedule

Net loss $20.8M in Q3 2023 vs $19.7M in Q3 2022; R&D spend rose to $17.1M from $9.9M.
August 28, 2023, 7:59 PM ET earnings materiality 0.85 positive item 2.02 item 9.01 ◈ Earnings Releases

Apogee Therapeutics Q2 net loss $18.9M; $345M IPO funds runway into 4Q26

Raised $345M in upsized July IPO; cash balance $125.1M at June 30; projected runway into 4Q 2026.
August 21, 2023, 7:59 PM ET leadership materiality 0.60 positive item 5.02 item 9.01 ◈ executive_change

Apogee Therapeutics appoints Mark C. McKenna as Chairman of Board

Mark C. McKenna appointed as Chairman and Class III director, effective August 17, 2023.
August 7, 2023, 7:59 PM ET other material materiality 0.60 positive item 7.01 item 9.01

Apogee initiates dosing in Phase 1 trial of APG777 ahead of schedule for atopic dermatitis

First participants dosed in healthy-volunteer Phase 1 trial of APG777 ahead of initial timeline.